 |
|
A novel clinical use for Mirvaso has been proposed by an article in the Australasian Journal of Dermatology.
Researchers are suggesting that Mirvaso can been used to differentiate between the redness associated with rosacea and the redness of sun damaged skin.
If the redness improves after application of Mirvaso then sun damage can be eliminated as the cause of the facial redness.
Australas J Dermatol 2016 Jan 13.
In this case report, we detail the response of a 37-year-old Caucasian man with an overlap of erythematotelangiectatic rosacea and telangiectatic photoaging to brimonidine tartrate gel.
With the application of brimonidine only on half of his face, skin analysis images, clinician’s and patient’s assessment showed that there was significant improvement in the erythema. This case has lent insight into how brimonidine can be used to assess the extent of photoaging by eliminating the erythema of rosacea to some degree.
We propose that it can be used as a non-invasive test to differentiate between the two conditions, sparing patients from skin biopsies and molecular analysis.
One might be left wondering, though, what doctors should assume if the facial redness is worsened by Mirvaso? OK this question is a bit tongue in cheek, a slight niggle because of the high reports of adverse reactions to Mirvaso.
